噬菌体疗法
医学
病毒学
重症监护医学
生物
噬菌体
大肠杆菌
遗传学
基因
作者
Koen Wortelboer,Hilde Herrema
标识
DOI:10.1016/j.tem.2024.03.007
摘要
Abstract
The worldwide prevalence of cardiometabolic diseases (CMD) is increasing, and emerging evidence implicates the gut microbiota in this multifactorial disease development. Bacteriophages (phages) are viruses that selectively target a bacterial host; thus, phage therapy offers a precise means of modulating the gut microbiota, limiting collateral damage on the ecosystem. Several studies demonstrate the potential of phages in human disease, including alcoholic and steatotic liver disease. In this opinion article we discuss the potential of phage therapy as a predefined medicinal product for CMD and discuss its current challenges, including the generation of effective phage combinations, product formulation, and strict manufacturing requirements.
科研通智能强力驱动
Strongly Powered by AbleSci AI